COCHLEAR News & Analysis

Thomas Rowe Price Jnr shocked Wall Street in the mid-60s by presciently selling growth stocks and buying real assets. His warnings to growth...

Wine is recession proof and Aussie unemployment falls to a 48 year low.

A busy week of results was overshadowed by a giant merger and the weakening economic outlook.

The wide-moat hearing implant maker was less affected by coronavirus elective surgery restrictions than analysts expected.

It’s the leader in medical device disinfection but patent expiry and the potential for copycats raise doubts, says Nicolette Quinn. 

Companies are turning to shareholders to help fund them through the pandemic, sometimes leaving them worse off.

Local names are tipped to rebound as the pandemic forces a contraction in Australia’s economy.

Investors have mostly made attractive returns by participating in these COVID-19 raisings, with a median return of 14 per cent for capital...

There are 14 names under Morningstar coverage and some have defensive qualities

Big discounts shouldn't be the deciding factor when considering the many rights issues flooding the Australian share market, says Morningstar's Peter...